Breaking

Music Review: Weezer’s self-titled ‘Gold Album’ delivers faithful, nasal power pop Psychologist testifies Lindsay Clancy was not criminally responsible in killing of her 3 children Rashford thanks Carragher after Neville comment Japan reports record exports and imports for July as energy costs climb Once homeless and in liquidation, Coventry back in the Premier League after painful 25-year absence New opposition group plans protest in Tunisia after extreme heat-driven power and water cuts US sends 20 deportees to Liberia, part of 1,200 migrants the country will receive under new deal Missing teen hiker found dead in Australian bush after eight-day search Record Heat Across US Has Millions Searching for Ways to Cope There is nothing scientific about The Great ADHD Myth? ‘documentary’ | Gina Rippon

NEWSREEL

The day, in 30-second reels.

--:--:--

World / Reel

World · Video brief

Repurposed drug may extend survival in aggressive ovarian cancer, trial shows

The Guardian· Apr 25, 2026 · 11:45 AM · 32 views

Video won't play? Watch on YouTube →

Exciting news from recent trials shows that relacorilant, a drug originally for Cushing’s syndrome, could extend the survival of ovarian cancer patients. The study revealed a 35% reduction in death risk and an average four-month increase in lifespan for those with platinum-resistant ovarian cancer. Discover more about these promising advancements in cancer treatment. #OvarianCancer #MedicalBreakthrough #CancerResearch #SurvivalRate #HealthNews

Originally reported by The Guardian. Read the full story →

0 Comments

No comments yet. Be the first.

Repurposed drug may extend survival in aggressive ovarian cancer, trial shows

More in World

US sends 20 deportees to Liberia, part of 1,200 migrants the country will receive under new deal

Missing teen hiker found dead in Australian bush after eight-day search

Record Heat Across US Has Millions Searching for Ways to Cope

0 Comments